MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
5.04
-0.01
-0.20%
After Hours: 4.920 -0.12 -2.38% 16:09 03/14 EDT
OPEN
5.10
PREV CLOSE
5.05
HIGH
5.23
LOW
4.970
VOLUME
66.43K
TURNOVER
--
52 WEEK HIGH
15.97
52 WEEK LOW
3.610
MARKET CAP
39.77M
P/E (TTM)
96.18
1D
5D
1M
3M
1Y
5Y
1D
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Seeking Alpha · 10h ago
Weekly Report: what happened at DTIL last week (0303-0307)?
Weekly Report · 5d ago
Weekly Report: what happened at DTIL last week (0224-0228)?
Weekly Report · 03/03 09:03
PRECISION BIOSCIENCES ANNOUNCES ORAL PRESENTATION AT THE 2025 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE
Reuters · 02/24 12:01
Weekly Report: what happened at DTIL last week (0217-0221)?
Weekly Report · 02/24 09:03
Buy Rating for Precision BioSciences: Promising Clinical Data and Undervaluation Highlight Favorable Risk/Reward Scenario
TipRanks · 02/20 12:46
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
Benzinga · 02/19 19:27
Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 02/19 16:43
More
About DTIL
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.